

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

L10I 99%
seen=1,776 • I13V 100%
seen=1,862 • E35D 98%
seen=2,362 • M36I 98%
seen=2,362 • R41K 99%
seen=2,306 • K43R 99%
seen=3,202 • L63T 98%
seen=2,603 • I64IL 1: 97%
seen=2,596 1: 47% • H69Q 99%
seen=2,536 • L89M 99%
seen=2,362

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

PR comments

Other

- L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

No drug resistance mutations were found for PI.

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

K20R 97%
seen=2,362 • V35IM 1: 47%
seen=2,362 30: 10% • T39TA 1: 10%
seen=2,322 1: 13% • E40D 70%
seen=3,367 • V60V 1: 10%
seen=3,333 1: 49% • K122V 95%
seen=3,349 • S162C 98%
seen=3,182 • T165I 100%
seen=3,349 • K173R 98%
seen=3,426 • Q174K 97%
seen=3,434 • D177E 98%
seen=3,207 • I178L 97%
seen=3,232 • V179I 98%
seen=3,291 • T200A 100%
seen=308 • Q207A 100%
seen=461 • R211NS 16: 10%
seen=523 16: 47% • V243Q 99%
seen=426 • E248ED 1: 10%
seen=422 1: 43%

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible	doravirine (DOR)	Potential Low-Level Resistance
zidovudine (AZT)	Susceptible	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	Susceptible	etravirine (ETR)	Susceptible
didanosine (DDI)	Susceptible	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	Susceptible	rilpivirine (RPV)	Susceptible
lamivudine (3TC)	Susceptible		
tenofovir (TDF)	Susceptible		

RT comments

NNRTI

- K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
- V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

No drug resistance mutations were found for NRTI.

Drug resistance mutation scores of NNRTI:

[Download CSV](#)

Rule	DOR	EFV	ETR	NVP	RPV
V108I	10	10	0	15	0
K103N	0	60	0	60	0
Total	10	70	0	75	0